CeriBell (NASDAQ:CBLL) Coverage Initiated by Analysts at Canaccord Genuity Group

Equities researchers at Canaccord Genuity Group assumed coverage on shares of CeriBell (NASDAQ:CBLL) in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 14.33% from the stock’s previous close.

A number of other research analysts also recently weighed in on CBLL. Canaccord Genuity Group started coverage on shares of CeriBell in a research report on Tuesday. They set a “buy” rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on CeriBell in a research note on Tuesday. They issued an “overweight” rating and a $32.00 price target on the stock. William Blair initiated coverage on CeriBell in a research report on Tuesday. They set an “outperform” rating for the company. TD Cowen initiated coverage on CeriBell in a research report on Tuesday. They issued a “buy” rating and a $31.00 target price on the stock. Finally, Bank of America started coverage on shares of CeriBell in a research report on Tuesday. They set a “buy” rating and a $32.00 price target for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $31.00.

CeriBell Trading Down 0.7 %

CBLL opened at $26.24 on Tuesday. CeriBell has a 52-week low of $23.00 and a 52-week high of $27.71.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.